Top Stories
Top Stories
Health and Science

Starboard reportedly target Magellan Health to explore potential sale

Key Points
  • U.S. healthcare plan and pharmacy benefits manager Magellan Health will explore selling itself after coming under pressure to do so from activist hedge fund Starboard Value LP, people familiar with the matter said on Wednesday.
  • Magellan is in the early stages of considering acquisition interest expressed in the company.
  • The company is advised by investment bank Goldman Sachs.
Jeffrey Smith, Starboard Value
David Grogan | CNBC

U.S. healthcare plan and pharmacy benefits manager Magellan Health will explore selling itself after coming under pressure to do so from activist hedge fund Starboard Value LP, people familiar with the matter said on Wednesday.

Magellan, advised by investment bank Goldman Sachs, is in the early stages of considering acquisition interest expressed in the company, the sources said, cautioning there is no certainty a deal will materialize.

The sources asked not to be identified because the matter is confidential. Magellan and Goldman Sachs did not immediately respond to requests for comment.

Next Article
Key Points
  • Starboard Value takes a 9.8 percent stake in health insurer and pharmacy-benefits manager Magellan Health.
  • A source familiar with the matter says the fund could consider advocating for a potential sale or managerial changes to help unlock shareholder value. 
  • The hedge fund also said that it may eventually decide to speak with Magellan to discuss issues including ownership structure and board composition.